Results 161 to 170 of about 1,331 (171)

Nitisinone use in hereditary tyrosinemia and alkaptonuria

2010
Wendy J. Introne, Kevin J. O'Brien, William A. Gahl   +2 more
openaire   +1 more source

The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool

Annals of Clinical Biochemistry, 2017
Andrew S Davison, Anna Milan, Lakshminarayan Ranganath   +2 more
exaly  

Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry

Annals of Clinical Biochemistry, 2015
Andrew S Davison, Anna Milan, Lakshminarayan Ranganath   +2 more
exaly  

LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE

2012
SVENSSON LENNART, SIDEN HANS
openaire   +5 more sources

Nitisinone for the treatment of alkaptonuria: FDA approval summary

Molecular Genetics and Metabolism
Daniela Varela Luquetti, Emily Morris
openaire   +1 more source

Efficacy and safety of Nitisinone for patients with alkaptonuria: A systematic review with metanalysis

Molecular Genetics and Metabolism
Flavia Diniz Mayrink, Camila Alves Areda
exaly  

Nitisinon experience in alkaptonuria patients

2019
ARSLAN, SEZAİ, Kadıoğlu Yılmaz, banu, KARDAŞ, FATİH, KENDİRCİ, MUSTAFA, Alakuş Sarı, Ümmü   +4 more
openaire   +1 more source

Human medicines European public assessment report (EPAR): Nitisinone MDK (previously Nitisinone MendeliKABS), nitisinone, Tyrosinemias, Date of authorisation: 24/08/2017, Revision: 2, Status: Authorised

Case Medical Research, 2019
openaire   +1 more source

In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.

The Medical letter on drugs and therapeutics, 2017
openaire   +1 more source

NITISINONE FOR TREATMENT OF OCULOCUTANEOUS/OCULAR ALBINISM AND FOR INCREASING PIGMENTATION

2011
BROOKS BRIAN P, GAHL WILLIAM A
openaire   +6 more sources